China-based CStone Pharmaceuticals (HKG: 2616) has announced the presentation of the latest clinical data on CS5001, an anti-ROR1 antibody drug conjugate (ADC) for lymphoma, at the 66th American Society of Hematology (ASH) Annual Meeting. CS5001 is a leading asset in CStone’s Pipeline 2.0 and has shown significant promise in treating patients with advanced B-cell lymphoma.
Clinical Data Highlights
As of the abstract data cutoff, CS5001 has achieved an objective response rate (ORR) of 43.5% among all evaluable patients with advanced B-cell lymphoma across all dose levels. Notably, from the initial effective dose, the Hodgkin lymphoma and the non-Hodgkin lymphoma subgroups have achieved ORRs of 60.0% and 50.0%, respectively. These results underscore the potential of CS5001 as an effective treatment option for lymphoma patients.
CS5001’s Unique Design and Mechanism
CS5001 is a clinical stage ROR1-targeted ADC that has been uniquely designed with a proprietary tumor-cleavable linker and pyrrolobenzodiazepine (PBD) prodrug. The innovative design ensures that the linker and prodrug are only cleaved upon reaching the tumor, releasing the PBD toxin and resulting in lethal DNA cross-links in cancer cells. This approach effectively addresses the toxicity issues associated with traditional PBD payloads, leading to a better safety profile for patients.
Development and Licensing Background
CS5001 was originally developed by LigaChem Biosciences, Inc. (LCB) and ABL Bio, both leading biotech companies based in South Korea. CStone in-licensed CS5001 from LigaChem Bio in October 2020 for global development and commercialization rights outside of South Korea. This licensing agreement has positioned CStone to bring this innovative therapy to a global patient population in need of new treatment options for lymphoma.- Flcube.com
